[go: up one dir, main page]

NO20064450L - Pyrazolo [3,4- β] Pyridin-forbindelse og dennes anvendelse som PDE4-inhibitor - Google Patents

Pyrazolo [3,4- β] Pyridin-forbindelse og dennes anvendelse som PDE4-inhibitor

Info

Publication number
NO20064450L
NO20064450L NO20064450A NO20064450A NO20064450L NO 20064450 L NO20064450 L NO 20064450L NO 20064450 A NO20064450 A NO 20064450A NO 20064450 A NO20064450 A NO 20064450A NO 20064450 L NO20064450 L NO 20064450L
Authority
NO
Norway
Prior art keywords
compound
pyrazolo
mammal
provides
salt
Prior art date
Application number
NO20064450A
Other languages
English (en)
Norwegian (no)
Inventor
Martin Redpath Johnson
Paul Spencer Jones
Caroline Mary Cook
Iv Siegfried Benja Christensen
Christopher David Edlin
Mika Kristian Lindvall
Naimisha Trivedi
Amyn Pyarali Sayani
Lionel Trottet
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0405893A external-priority patent/GB0405893D0/en
Priority claimed from GB0505214A external-priority patent/GB0505214D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20064450L publication Critical patent/NO20064450L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
NO20064450A 2004-03-16 2006-10-02 Pyrazolo [3,4- β] Pyridin-forbindelse og dennes anvendelse som PDE4-inhibitor NO20064450L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0405893A GB0405893D0 (en) 2004-03-16 2004-03-16 Compounds
GB0505214A GB0505214D0 (en) 2005-03-14 2005-03-14 Compounds
PCT/EP2005/003038 WO2005090352A1 (fr) 2004-03-16 2005-03-15 Compose de pyrazolo[3,4-b]pyridine, et son utilisation en tant qu'inhibiteur de pdea4

Publications (1)

Publication Number Publication Date
NO20064450L true NO20064450L (no) 2006-11-14

Family

ID=34962723

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064450A NO20064450L (no) 2004-03-16 2006-10-02 Pyrazolo [3,4- β] Pyridin-forbindelse og dennes anvendelse som PDE4-inhibitor

Country Status (15)

Country Link
US (2) US7709497B2 (fr)
EP (2) EP1735314A1 (fr)
JP (2) JP2007529464A (fr)
KR (1) KR20060130744A (fr)
AR (1) AR048175A1 (fr)
AU (1) AU2005223351A1 (fr)
BR (1) BRPI0508843A (fr)
CA (1) CA2559629A1 (fr)
IL (1) IL178011A0 (fr)
MA (1) MA28531B1 (fr)
NO (1) NO20064450L (fr)
PE (1) PE20060078A1 (fr)
RU (1) RU2378274C2 (fr)
TW (1) TW200602051A (fr)
WO (2) WO2005090354A1 (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
US20070111995A1 (en) * 2003-12-19 2007-05-17 Allen David G Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors
EP1735314A1 (fr) 2004-03-16 2006-12-27 Glaxo Group Limited Compose de pyrazolo [3,4-b]pyridine, et son utilisation en tant qu'inhibiteur de pdea4
AU2007242851A1 (en) 2006-04-20 2007-11-01 Glaxo Group Limited Novel compounds
PE20080943A1 (es) 2006-06-23 2008-09-27 Smithkline Beecham Corp Sal toluenosulfonato de 4-{[6-cloro-3-({[(2-cloro-3-fluorofenil)amino]carbonil}amino)-2-hidroxifenil]sulfonil}-1-piperazinacarboxilato de 1,1-dimetiletilo como antagonista del receptor de il-8
DK2046787T3 (da) 2006-08-01 2011-07-18 Glaxo Group Ltd Pyrazolo[3,4-B]pyridin-forbindelser, og deres anvendelse som PDE4-inhibitorer
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
AR070563A1 (es) 2008-02-06 2010-04-21 Glaxo Group Ltd Compuesto de un biciclo condensado pirazol-piridin-amina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de enfermedades respiratorias.
UY31635A1 (es) 2008-02-06 2009-08-31 Farmacóforos duales-antagonistas muscarínicos de pde4
TW201000476A (en) 2008-02-06 2010-01-01 Glaxo Group Ltd Dual pharmacophores-PDE4-muscarinic antagonistics
EP2249646A4 (fr) * 2008-02-06 2013-09-25 Glaxo Group Ltd Pharmacophores duals, antagonistes des récepteurs muscariniques et inhibiteurs de l'activité pde4
GB0806900D0 (en) * 2008-04-16 2008-05-21 Dow Corning Fabric care emulsions
US8163743B2 (en) 2008-06-05 2012-04-24 GlaxoGroupLimited 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases
CA2749403A1 (fr) 2009-01-13 2010-09-02 Glaxo Group Limited Derives de pyrimidine carboxamide comme inhibiteurs de la kinase syk
JP5656880B2 (ja) 2009-03-09 2015-01-21 グラクソ グループ リミテッドGlaxo Group Limited Pi3キナーゼの阻害剤としての4−オキサジアゾール−2−イル−インダゾール
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
EP2408769A1 (fr) 2009-03-17 2012-01-25 Glaxo Group Limited Dérivés de pyrimidine utilisés comme inhibiteurs de ltk
CA2795611C (fr) * 2009-04-13 2016-09-20 Sulur Subramaniam Vanangamudi Creme medicinale a base d'acide fusidique produite au moyen de fusidate de sodium et incorporant un biopolymere et son procede de fabrication
MY160454A (en) 2009-04-30 2017-03-15 Glaxo Group Ltd Oxazole substituted indazoles as pi3-kinase inhibitors
WO2011067364A1 (fr) 2009-12-03 2011-06-09 Glaxo Group Limited Nouveaux composés
US20120245171A1 (en) 2009-12-03 2012-09-27 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of pi3 kinases
WO2011067366A1 (fr) 2009-12-03 2011-06-09 Glaxo Group Limited Dérivés d'indazole comme inhibiteurs des pi3-kinases
WO2011110575A1 (fr) 2010-03-11 2011-09-15 Glaxo Group Limited Dérivés de 2-[2-(benzo- ou pyrido-)thiazolylamino]-6- aminopyridine, utiles dans le traitement de maladies respiratoires, allergiques ou inflammatoires
US9326987B2 (en) 2010-09-08 2016-05-03 Glaxo Group Limited Indazole derivatives for use in the treatment of influenza virus infection
DK2614058T3 (en) 2010-09-08 2015-09-28 Glaxosmithkline Ip Dev Ltd Polymorphs, and the salts of N- [5- [4- (5 - {[(2R, 6S) -2,6-dimethyl-4-morpholinyl] methyl} -1,3-oxazol-2-yl) -1H-indazole -6-yl] -2- (methyloxy) -3-pyridinyl] methanesulfonamide.
WO2012035055A1 (fr) 2010-09-17 2012-03-22 Glaxo Group Limited Nouveaux composés
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
KR102142162B1 (ko) 2012-08-27 2020-09-14 에이비 엘렉트로룩스 로봇 위치 선정 시스템
CN105101854A (zh) 2013-04-15 2015-11-25 伊莱克斯公司 机器人真空吸尘器
WO2014169944A1 (fr) 2013-04-15 2014-10-23 Aktiebolaget Electrolux Dispositif de nettoyage sous vide robotisé avec brosse latérale saillante
US9011934B2 (en) 2013-06-14 2015-04-21 SatisPharma, LLC Multi-purpose anti-itch treatment
AU2014336251A1 (en) 2013-10-17 2016-04-14 Glaxosmithkline Intellectual Property Development Limited PI3K inhibitor for treatment of respiratory disease
RU2016112268A (ru) 2013-10-17 2017-11-22 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Ингибитор PI3K для лечения респираторного заболевания
CN105813526B (zh) 2013-12-19 2021-08-24 伊莱克斯公司 机器人清扫装置以及用于地标识别的方法
KR102099495B1 (ko) 2013-12-19 2020-04-09 에이비 엘렉트로룩스 로봇 청소 장치가 장애물에 올라가는 것의 감지
CN105744872B (zh) 2013-12-19 2020-01-14 伊莱克斯公司 旋转侧刷的自适应速度控制
WO2015090404A1 (fr) 2013-12-19 2015-06-25 Aktiebolaget Electrolux Priorisation de zones de nettoyage
ES2656664T3 (es) 2013-12-19 2018-02-28 Aktiebolaget Electrolux Dispositivo robótico de limpieza con función de registro del perímetro
EP3084540B1 (fr) 2013-12-19 2021-04-14 Aktiebolaget Electrolux Robot de nettoyage et methode d'exploitation associee
WO2015090398A1 (fr) 2013-12-19 2015-06-25 Aktiebolaget Electrolux Aspirateur robotique ayant une brosse latérale se déplaçant en spirale
CN105848545B (zh) 2013-12-20 2019-02-19 伊莱克斯公司 灰尘容器
EA201692111A1 (ru) 2014-05-12 2017-08-31 Глаксосмитклайн Интеллекчуал Проперти (№ 2) Лимитед Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
CN106415423B (zh) 2014-07-10 2021-01-01 伊莱克斯公司 用于检测机器人清洁装置的测量误差的方法
KR102271785B1 (ko) 2014-09-08 2021-06-30 에이비 엘렉트로룩스 로봇 진공 청소기
US10729297B2 (en) 2014-09-08 2020-08-04 Aktiebolaget Electrolux Robotic vacuum cleaner
US9452178B1 (en) 2014-10-22 2016-09-27 SatisPharma, LLC Acne formulations, treatments, and pressure sensitive patches for delivery of acne formulations
CN106998980B (zh) 2014-12-10 2021-12-17 伊莱克斯公司 使用激光传感器检测地板类型
WO2016091320A1 (fr) 2014-12-12 2016-06-16 Aktiebolaget Electrolux Brosse latérale et dispositif de nettoyage robotisé
WO2016095965A2 (fr) 2014-12-16 2016-06-23 Aktiebolaget Electrolux Feuille de route basée sur l'expérience pour un dispositif de nettoyage robotisé
WO2016095966A1 (fr) 2014-12-16 2016-06-23 Aktiebolaget Electrolux Procédé de nettoyage pour un dispositif de nettoyage robotisé
EP3282912B1 (fr) 2015-04-17 2020-06-10 Aktiebolaget Electrolux Dispositif robotique de nettoyage et un procédé de contrôle pour le dispositif robotique de nettoyage
KR102445064B1 (ko) 2015-09-03 2022-09-19 에이비 엘렉트로룩스 로봇 청소 장치의 시스템
PT3359541T (pt) * 2015-10-09 2020-11-11 Galapagos Nv Pirazol[3,4-b]piridin-6-carboxamidas n-sulfoniladas e método de utilização
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
JP7035300B2 (ja) 2016-03-15 2022-03-15 アクチエボラゲット エレクトロルックス ロボット清掃デバイス、ロボット清掃デバイスにおける、断崖検出を遂行する方法、コンピュータプログラム、およびコンピュータプログラム製品
EP3454707B1 (fr) 2016-05-11 2020-07-08 Aktiebolaget Electrolux Robot de nettoyage
WO2018029126A1 (fr) 2016-08-08 2018-02-15 Glaxosmithkline Intellectual Property Development Limited Composés chimiques
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
WO2018219473A1 (fr) 2017-06-02 2018-12-06 Aktiebolaget Electrolux Procédé de détection d'une différence de niveau d'une surface devant un dispositif de nettoyage robotisé
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN111093447B (zh) 2017-09-26 2022-09-02 伊莱克斯公司 机器人清洁设备的移动控制
KR102034538B1 (ko) * 2017-11-28 2019-10-21 주식회사한국파마 Jak 저해제 화합물, 및 이의 제조방법
CN111875594A (zh) * 2020-07-21 2020-11-03 中国药科大学 具有磷酸二酯酶4b抑制活性的吲唑杂环类化合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833594A (en) * 1971-08-05 1974-09-03 Squibb & Sons Inc Amino derivatives of pyrazolopyridine carboxylic acids and esters
US3925388A (en) * 1971-08-05 1975-12-09 Squibb & Sons Inc 4-Piperazino-{8 3,4-b{9 pyridine-5-carboxylic acids and esters
US3856799A (en) * 1971-08-05 1974-12-24 Squibb & Sons Inc Intermediates for production of amino derivatives of pyrazolopyridine carboxylic acids and esters
BE787249A (fr) * 1971-08-05 1973-02-05 Squibb & Sons Inc Derives amino d'acides pyrazolopyridine carboxyliques, leurs esters et les sels de ces composes, ainsi que leurs procedes de preparation
CA1003419A (en) 1971-11-23 1977-01-11 Theodor Denzel Process for the production of pyrazolo (3,4-b) pyridines
US3979399A (en) * 1972-11-15 1976-09-07 E. R. Squibb & Sons, Inc. Amino derivatives of pyrazolopyridine carboxamides
US3840546A (en) * 1972-11-15 1974-10-08 Squibb & Sons Inc Amino derivatives of pyrazolopyridine carboxamides
US3833598A (en) * 1972-12-29 1974-09-03 Squibb & Sons Inc Amino derivatives of pyrazolopyridine-6-carboxylic acids and esters
US4115394A (en) * 1974-05-06 1978-09-19 E. R. Squibb & Sons, Inc. Amino derivatives of 6-phenylpyrazolo[3,4-b]pyridines
US4364948A (en) 1981-09-28 1982-12-21 Ici Americas Inc. Pyrazolo[3,4-b]pyridine compounds
GB8425104D0 (en) 1984-10-04 1984-11-07 Ici America Inc Amide derivatives
US5547954A (en) * 1994-05-26 1996-08-20 Fmc Corporation 2,4-Diamino-5,6-disubstituted-and 5,6,7-trisubstituted-5-deazapteridines as insecticides
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US6326379B1 (en) * 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
RU2134498C1 (ru) * 1998-12-08 1999-08-10 Таран Александр Иванович Контактный узел
CZ20021086A3 (cs) 1999-09-30 2002-10-16 Neurogen Corporation Alkylendiaminem substituované heterocykly
GB9929685D0 (en) 1999-12-15 2000-02-09 Merck Sharp & Dohme Therapeutic agents
JP2002020386A (ja) * 2000-07-07 2002-01-23 Ono Pharmaceut Co Ltd ピラゾロピリジン誘導体
US6670364B2 (en) * 2001-01-31 2003-12-30 Telik, Inc. Antagonists of MCP-1 function and methods of use thereof
WO2002098878A1 (fr) 2001-02-08 2002-12-12 Memory Pharmaceuticals Corporation Trifluoromethylpurines en tant qu'inhibiteurs de la phosphodiesterase 4
TWI236474B (en) 2001-04-03 2005-07-21 Telik Inc Antagonists of MCP-1 function and methods of use thereof
FR2828693B1 (fr) * 2001-08-14 2004-06-18 Exonhit Therapeutics Sa Nouvelle cible moleculaire de la neurotoxicite
US20050043319A1 (en) * 2001-08-14 2005-02-24 Exonhit Therapeutics Sa Molecular target of neurotoxicity
GB0230045D0 (en) * 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
US20060089375A1 (en) * 2002-09-16 2006-04-27 Allen David G Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors
US7117650B2 (en) * 2002-12-09 2006-10-10 Forrest Dockery Hanger system
US20070111995A1 (en) * 2003-12-19 2007-05-17 Allen David G Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors
EP1735314A1 (fr) 2004-03-16 2006-12-27 Glaxo Group Limited Compose de pyrazolo [3,4-b]pyridine, et son utilisation en tant qu'inhibiteur de pdea4
GB0405933D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
GB0405937D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
KR20060130744A (ko) 2006-12-19
BRPI0508843A (pt) 2007-08-28
US20070280971A1 (en) 2007-12-06
RU2378274C2 (ru) 2010-01-10
IL178011A0 (en) 2006-12-31
AU2005223351A1 (en) 2005-09-29
WO2005090352A1 (fr) 2005-09-29
JP2007529464A (ja) 2007-10-25
EP1735314A1 (fr) 2006-12-27
US20080275078A1 (en) 2008-11-06
EP1740590A1 (fr) 2007-01-10
MA28531B1 (fr) 2007-04-03
US7709497B2 (en) 2010-05-04
TW200602051A (en) 2006-01-16
JP2007529486A (ja) 2007-10-25
WO2005090354A1 (fr) 2005-09-29
CA2559629A1 (fr) 2005-09-29
RU2006132684A (ru) 2008-04-27
AR048175A1 (es) 2006-04-05
PE20060078A1 (es) 2006-03-10

Similar Documents

Publication Publication Date Title
NO20064450L (no) Pyrazolo [3,4- β] Pyridin-forbindelse og dennes anvendelse som PDE4-inhibitor
NO20071776L (no) Kinoksaliner som B RAF inhibitorer.
NO20055421L (no) Kinolinderivater som fosfodiestrase-inhibitorer
NO20066055L (no) Pyridinderivater
NO20061454L (no) Compounds having CRTH2 antagonist activity
NO20084872L (no) 2-pyridonderivater for behandling av sykdom eller tilstander der inhibering av neutrofil elastaseaktivitet er gunstig
MXPA05010055A (es) Derivados de 2-fenoxi- y 2-fenil-sulfomamida con actividad antagonista del ccr3, para el tratamiento del asma y otros desordenes inflamatorios o inmunologicos.
NO20044599L (no) 3-amino-tieno[2,3-b]pyridin-2-karboksysyreamid-forbindelser og fremgangsmater for fremstilling og anvendelser av dem
WO2007040438A3 (fr) Derives d'imidazo(4,5-b) pyridine utilises comme inhibiteurs de la glycogene synthase kinase 3 pour le traitement de la demence et de troubles neurodegeneratifs
NO20070199L (no) Substituerte kinazoloner som anti-kreftmidler
WO2007044085A3 (fr) Composes heteroaryle et leurs utilisations en tant qu'agents therapeutiques
NO20070432L (no) Pyrimidinureaderivater som kinaseinhibitorer
NO20080408L (no) Azaindazolforbindelser og anvendelse derav
NO20075059L (no) Nye forbindelser II 2-pyridinderivater som inhibitorer av neutrofil elastase
NO20100827L (no) Glukocorticoid-mimetica, fremgangsmater for fremstilling av dem, farmasoytiske blandinger, og anvendelser derav
NO20071246L (no) Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
NO20072259L (no) Heteroaryltiazoler og deres anvendelse som P13K-inhibitorer
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
NO20081349L (no) Pyrrolopyrimidinderivater som Syk-inhibitorer
NO20052802L (no) Pyrrolopyrimidinderivativer
NO20072784L (no) Pyridenkarboksamidderivater for anvendelse som anticancer midler
WO2008045664A3 (fr) Inhibiteurs hétérocycliques de pde4
WO2005049581A8 (fr) Derives de pyridazine-3(2h)-ones et utilisation en tant qu'inhibiteurs de pde4
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
WO2002083667A3 (fr) Inhibiteurs de c-jun n-terminal kinases (jnk) et d'autres proteines kinases

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application